

Haematologica
HAEMATOL/2017/182352
Version 3

Increased rituximab exposure does not improve response and outcome of CLL patients after FCR. A French Innovative Leukemia Organization (FILO) Study.

Guillaume Cartron, Rémi Letestu, Caroline Dartigeas, Mira Tout, Béatrice Mahé, Anne-Laure Gagez, Emmanuelle Ferrant, Boris Guiu, Bruno Villemagne, Phan Letuan, Thérèse Aurrant, Frédéric Orsini-Piocelle, Anne Banos, Pierre Feugier, Véronique Leblond, Sophie de Guibert, Olivier Tournihac, Jehan Dupuis, Alain Delmer, Valérie Rouillé, David Ternant, and Stéphane Leprêtre

Disclosures: Consultancy within the past two years: Guillaume Cartron (GC), Caroline Dartigeas (CD), Rémi Letestu (RL) and Jehan Dupuis (JD). Honoraria directly received from an entity: Guillaume Cartron (GC). All other authors have no conflicts of interest.

Contributions: Designed research: GC, DT, SL Performed research: GC, RL, CD, MT, BM, ALG, EF, BG, BV, PL, TA, BC, AB, PF, VM, SdG, OT, JD, AD, DT, SL Collected data: GC, ALG, MT, SL Analyzed and interpreted data: GC, ALG, MT, DT, SL Performed statistical analysis: PL, ALG, MT Wrote/reviewed the manuscript: GC, ALG, MT, DT, SL Approved manuscript: GC, RL, CD, MT, BM, ALG, EF, BG, BV, PL, TA, BC, AB, PF, VM, SdG, OT, JD, AD, VR, DT, SL